Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| UR Anoop Research Group | OTHER |
Not provided
Not provided
Not provided
Not provided
During the peak of the second COVID -19 wave, the hospitals were over-crowded. Many COVID -19 positive patients had to stay at home and reach out to their family physicians for guidance. Medical follow-up for these patients was a daunting challenge. As in - patient hospital facilities were not readily accessible due to over crowding, early objective tests to identify home quarantined patients prone to deterioration and timely medical intervention to avoid hospitalization were required.
Based on early assessment of inflammatory markers like CRP and clinical signs like persistent high-grade fever, need-based early medical intervention was initiated in home quarantined COVID -19 patients prior to the onset of hypoxia, in order to avoid complications and hospitalization
25 home quarantined COVID -19 patients who contacted online for medical guidance underwent clinical and biochemical evaluation. Radiological evaluation was done only if indicated.
Based on early objective biochemical tests like elevated CRP and clinical signs like persistent high-grade fever on the third or fourth day after onset of symptoms, early medical treatment was initiated prior to onset of hypoxia.
All the 25 patients recovered without any complications and did not require hospitalization.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Mild | Experimental | Patients with mild symptoms and normal CRP. |
|
| Moderate | Experimental | Patients with mild symptoms and less than 10 fold increase in CRP. |
|
| Severe | Experimental | Patients with high grade fever persisting even on the third or fourth day after onset of symptoms or 10 fold or more increase in CRP. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Oral Antibiotic, Antihistamine, Anti-inflammatory, Multivitamins | Drug | Oral Azithromycin , Cetirizine, Paracetamol, Zinc, Vitamin C, Vitamin D |
|
| Measure | Description | Time Frame |
|---|---|---|
| Number of home quarantined COVID -19 positive patients requiring admission in a hospital for hypoxia. | Oxygen saturation in COVID-19 positive patients was monitored using pulse oximetry at home. Those patients who developed hypoxia (less than 94%) were referred for hospitalization. | Two weeks from the onset of symptoms. |
| Measure | Description | Time Frame |
|---|---|---|
| Number of home quarantined COVID -19 patients developing thromboembolic complications | Thromboembolic complications in COVID-19 positive patients under home quarantine were assessed using an online questionnaire. | Four weeks from the time of initial presentation |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| MANIMARANE ARJUNAN, MD,DM-CARDIO | UR Anoop Research Group | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| ONLINE | Puducherry | India |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Oral low dose steroid | Drug | Low dose oral methyl prednisolone was added. |
|
| Intravenous Antibiotics with Low dose steroid. | Drug | Intravenous ceftriaxone with either oral methyl prednisolone or intravenous dexamethasone was given |
|
| Oral anti-coagulant | Drug | Rivaroxaban was given for minimum 4 weeks depending on D dimer levels |
|
| ID | Term |
|---|---|
| D000086382 | COVID-19 |
| ID | Term |
|---|---|
| D011024 | Pneumonia, Viral |
| D011014 | Pneumonia |
| D012141 | Respiratory Tract Infections |
| D007239 | Infections |
| D014777 | Virus Diseases |
| D018352 | Coronavirus Infections |
| D003333 | Coronaviridae Infections |
| D030341 | Nidovirales Infections |
| D012327 | RNA Virus Infections |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D000900 | Anti-Bacterial Agents |
| D006633 | Histamine Antagonists |
| D000893 | Anti-Inflammatory Agents |
| C067316 | Geritol |
| D013256 | Steroids |
| D000925 | Anticoagulants |
| ID | Term |
|---|---|
| D000890 | Anti-Infective Agents |
| D045506 | Therapeutic Uses |
| D020228 | Pharmacologic Actions |
| D020164 | Chemical Actions and Uses |
| D018494 | Histamine Agents |
| D018377 | Neurotransmitter Agents |
| D045504 | Molecular Mechanisms of Pharmacological Action |
| D045505 | Physiological Effects of Drugs |
| D000072473 | Fused-Ring Compounds |
| D011083 | Polycyclic Compounds |
| D006401 | Hematologic Agents |
Not provided
Not provided